Soligenix, Inc. - Common Stock (SNGX)

Get a pulse on the US markets on Thursday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast.

Soligenix Targets Psoriasis With New Therapy

Soligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing.

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL

Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks.

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs

Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.